|
Highlights from ASCO 2001 Nearly 25,000 cancer specialists from around the world gathered at the 37th annual meeting of the American Society of Clinical Oncology (ASCO) in San Francisco, Calif., from May 12-15, 2001. Scientists there presented the latest advances in cancer research.
Listed below are links to articles discussing highlights of the meeting.
 Back to Top
Gleevec™ Shows Promise for Type of Gastrointestinal Tumor
(Posted: 07/20/2001, Updated: 04/14/2003) - Gleevec™, a new cancer drug approved on May 10, 2001, for the treatment of some types of leukemia, now appears also to work in a rare type of cancer called gastrointestinal stromal tumor (GIST). Two reports presented from early clinical trials of the drug, also called STI571, were presented at the 2001 annual meeting of the American Society of Clinical Oncology in San Francisco on May 14.
Chemotherapy and Radiation Together May Help Save Voicebox
(Posted: 05/14/2001, Updated: 11/27/2003) - People with cancer of the larynx often face laryngectomy -- surgery to remove the voicebox -- to help stop the spread of the cancer. Now, a new study shows that giving chemotherapy and radiation therapy together can put off the need for a laryngectomy and preserve use of the voicebox longer than the currently established practice of giving chemotherapy followed by radiation.
Pre-Surgical Chemotherapy May Improve Survival in Bladder Cancer
(Posted: 05/14/2001, Updated: 08/28/2003) - Chemotherapy before surgery nearly doubles survival rates in patients with locally advanced bladder cancer compared to surgery alone, according to a trial reported at the annual meeting of the American Society of Clinical Oncology in San Francisco on May 14.
Reducing Depression Does Not Reduce Fatigue
(Posted: 05/14/2001) - Cancer patients often experience both depression and fatigue, and physicians have had good reason to think that relieving depression might also reduce fatigue. But a new large randomized trial has disproved that theory and shifted researchers' attention to other possible strategies to fight cancer-related fatigue.
High Doses of Chemotherapy Drug Lead to Better Survival for Children with Leukemia and Lymphoma
(Posted: 05/14/2001, Reviewed: 03/15/2006) - Higher doses of a common chemotherapy drug, methotrexate, may lead to less recurrences of a certain type of leukemia and lymphoma in children.
Breast Cancer Transplant Trials Continue to Show No Benefit
(Posted: 05/12/2001) - The final analysis of data from one of the major U.S. trials of high-dose chemotherapy with stem cell transplant for breast cancer shows that it holds no survival advantage over intermediate-dose therapy. The findings from the trial, known as CALGB 9082, were presented today at the annual meeting of the American Society of Clinical Oncology (ASCO) in San Francisco.
|
